ARTICLE | Clinical News
EC approves Diurnal's Alkindi
February 16, 2018 1:03 PM UTC
Diurnal Group plc (LSE:DNL) said the European Commission approved Alkindi (Infacort) as a replacement therapy to treat adrenal insufficiency in individuals less than 18 years old. Diurnal plans to launch Alkindi in 2Q18, but told BioCentury it was "too early" to discuss pricing...
BCIQ Company Profiles